- Previous Close
33.62 - Open
33.83 - Bid 24.79 x 200
- Ask 43.46 x 200
- Day's Range
33.12 - 35.09 - 52 Week Range
18.94 - 43.11 - Volume
601,048 - Avg. Volume
602,121 - Market Cap (intraday)
1.68B - Beta (5Y Monthly) 1.54
- PE Ratio (TTM)
-- - EPS (TTM)
-0.95 - Earnings Date Apr 29, 2025 - May 5, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
52.22
AtriCure, Inc. develops, manufactures, and sells devices for surgical ablation of cardiac tissue, exclusion of the left atrial appendage, and temporarily blocking pain by ablating peripheral nerves to medical centers in the United States, the Asia-Pacific, and internationally. The company offers Isolator Synergy Clamps, a single-use disposable radio frequency products; multifunctional pens and linear ablation devices, a single-use disposable RF products for the treatment of cardiac arrhythmias; cryoICE Cryoablation System that enables the user to make linear ablations of varied lengths; and EPi-Sense Systems, a single-use disposable device used for the treatment of symptomatic, drug-refractory, and long-standing persistent atrial fibrillation. It also provides cryoSPHERE probe, which provides temporary pain relief by applying cryothermic energy to targeted intercoastal peripheral nerves in the ribcage; AtriClip System, an implantable device coupled to a single-use disposable applier; LARIAT System, a solution for soft-tissue closure; Lumitip dissectors to separate tissues to provide access to key anatomical structures that are targeted for ablation; Glidepath guides for placement of clamps; and Subtle Cannula's to support access for EPi-Sense catheters. In addition, the company sells various reusable cardiac surgery instruments. It markets and sells its products through independent distributors and direct sales personnel. The company was incorporated in 2000 and is headquartered in Mason, Ohio.
www.atricure.com1,300
Full Time Employees
December 31
Fiscal Year Ends
Sector
Medical Instruments & Supplies
Industry
Recent News: ATRC
View MorePerformance Overview: ATRC
Trailing total returns as of 3/27/2025, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: ATRC
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: ATRC
View MoreValuation Measures
Market Cap
1.68B
Enterprise Value
1.63B
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
3.47
Price/Book (mrq)
3.64
Enterprise Value/Revenue
3.51
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
-9.61%
Return on Assets (ttm)
-4.09%
Return on Equity (ttm)
-9.64%
Revenue (ttm)
465.31M
Net Income Avi to Common (ttm)
-44.7M
Diluted EPS (ttm)
-0.95
Balance Sheet and Cash Flow
Total Cash (mrq)
122.72M
Total Debt/Equity (mrq)
16.60%
Levered Free Cash Flow (ttm)
-10.42M